Long intergenic non-protein coding RNA 1056 (LINC01056)

Long intergenic non-protein coding RNA 1056 (LINC01056) is a long intergenic non-coding RNA, a transcript longer than 200 nucleotides that does not overlap with protein-coding genes and is primarily located in the nucleus[1][3][9]. It is classified within the families of lincRNAs and long non-coding RNAs, molecules that regulate gene expression epigenetically or transcriptionally, often acting as modulators of chromatin structure or mRNA processing[3][5][9]. LINC01056 has been identified as a key regulator of metabolic reprogramming and drug resistance in cancers, specifically acting as a negative regulator of sorafenib sensitivity in hepatocellular carcinoma (HCC)[2][4]. Knockdown of LINC01056 activates PPARα, which increases fatty acid metabolism and decreases glycolysis, thereby resensitizing cells to sorafenib. While not a canonical therapeutic target like proteins or receptors, LINC01056 is implicated in cancer progression, prognosis, and resistance phenotypes, making it a candidate for biomarker or therapeutic intervention research rather than a direct drug target[2][4].

Other names

LINC01056long intergenic non-protein coding RNA 1056

Modulation of peroxisome proliferator-activated receptor alpha (PPARα) activity, Regulation of fatty acid metabolism and glycolysis in cancer cells influencing drug resistance